{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:09:31Z","timestamp":1793736571514,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPD1M0411"],"award-info":[{"award-number":["CMRPD1M0411"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG3K0861-2"],"award-info":[{"award-number":["CMRPG3K0861-2"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Council, Taiwan","award":["MOST109-2221-E-182-045-MY3"],"award-info":[{"award-number":["MOST109-2221-E-182-045-MY3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with type 2 diabetes are at increased risk for cardiovascular diseases. Sodium-glucose transport 2 inhibitors (SGLT2i) have been shown to enhance cardiovascular health since their debut as a second-line therapy for diabetes. Acute coronary syndrome (ACS), peripheral arterial occlusive disease (PAOD), and ischemic stroke (IS) are types of atherosclerotic cardiovascular disease (ASCVD), although the benefits of treating these disorders have not been shown consistently.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched four databases (PubMed, Embase, the Cochrane library, and clinicaltrial.gov) for randomized clinical trials (RCTs) until November of 2022. Comparisons were made between SGLT2i-treated and control individuals with type 2 diabetes. Primary outcomes were ACS, PAOD, and\u00a0IS; secondary outcomes included cardiovascular mortality and all-cause mortality. Risk ratio (RR) and 95% confidence intervals (CI) were determined using a fixed effects model. Cochrane's risk-of-bias (RoB2) instrument was used to assess the validity of each study that met the inclusion criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We enrolled 79,504 patients with type 2 diabetes from 43 RCTs. There was no difference in the risk of ACS (RR\u2009=\u20090.97, 95% CI 0.89\u20131.05), PAOD (RR\u2009=\u20090.98, 95% CI 0.78\u20131.24), or IS (RR\u2009=\u20090.95, 95% CI 0.79\u20131.14) among patients who took an SGLT2i compared to those who took a placebo or oral hypoglycemic drugs. Subgroup analysis revealed that none of the SGLT2i treatments (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) significantly altered outcomes when analyzed separately. Consistent with prior findings, SGLT2i reduced the risk of cardiovascular mortality (RR\u2009=\u20090.85, 95% CI 0.77\u20130.93) and all-cause mortality (RR\u2009=\u20090.88, 95% CI 0.82\u20130.94).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results appear to contradict the mainstream concepts regarding the cardiovascular effects of SGLT2i since we found no significant therapeutic benefits in SGLT2i to reduce the incidence of ACS, PAOD, or IS when compared to placebo or oral hypoglycemic drugs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01789-5","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T14:03:49Z","timestamp":1678716229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Pei-Chien","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Min-Shan","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Shuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hsin","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"issue":"Suppl 1","key":"1789_CR1","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125\u201343.","journal-title":"Diabetes Care"},{"issue":"1","key":"1789_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11\u201326.","journal-title":"Nat Rev Nephrol"},{"issue":"16","key":"1789_CR3","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3390\/ijerph16162965","volume":"16","author":"A Tentolouris","year":"2019","unstructured":"Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health. 2019;16(16):2965.","journal-title":"Int J Environ Res Public Health."},{"issue":"1","key":"1789_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","volume":"21","author":"AD Kaze","year":"2022","unstructured":"Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol. 2022;21(1):47.","journal-title":"Cardiovasc Diabetol"},{"key":"1789_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110200","volume":"195","author":"GC Chan","year":"2023","unstructured":"Chan GC, Ng JK, Chow KM, Szeto CC. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: a population-based propensity score-matched cohort study. Diabetes Res Clin Pract. 2023;195: 110200.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1789_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12933-022-01574-w","volume":"21","author":"M Li","year":"2022","unstructured":"Li M, Yi T, Fan F, Qiu L, Wang Z, Weng H, Ma W, Zhang Y, Huo Y. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):139.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1789_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.hfc.2022.03.010","volume":"18","author":"PS Jhund","year":"2022","unstructured":"Jhund PS. SGLT2 inhibitors and heart failure with preserved ejection fraction. Heart Fail Clin. 2022;18(4):579\u201386.","journal-title":"Heart Fail Clin"},{"key":"1789_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101549","volume":"64","author":"A Elrakaybi","year":"2022","unstructured":"Elrakaybi A, Laubner K, Zhou Q, Hug MJ, Seufert J. Cardiovascular protection by SGLT2 inhibitors\u2014Do anti-inflammatory mechanisms play a role? Mol Metab. 2022;64: 101549.","journal-title":"Mol Metab"},{"issue":"1","key":"1789_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","volume":"21","author":"S Chen","year":"2022","unstructured":"Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol. 2022;21(1):45.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1789_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2337\/dc18-1773","volume":"42","author":"MP Bancks","year":"2019","unstructured":"Bancks MP, Ning H, Allen NB, Bertoni AG, Carnethon MR, Correa A, Echouffo-Tcheugui JB, Lange LA, Lloyd-Jones DM, Wilkins JT. Long-term absolute risk for cardiovascular disease stratified by fasting glucose level. Diabetes Care. 2019;42(3):457\u201365.","journal-title":"Diabetes Care"},{"issue":"4","key":"1789_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pcad.2019.07.001","volume":"62","author":"AJ Nelson","year":"2019","unstructured":"Nelson AJ, Peterson ED, Pagidipati NJ. Atherosclerotic cardiovascular disease and heart failure: determinants of risk and outcomes in patients with diabetes. Prog Cardiovasc Dis. 2019;62(4):306\u201314.","journal-title":"Prog Cardiovasc Dis"},{"issue":"9","key":"1789_CR12","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.7150\/thno.54498","volume":"11","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ma X, Ilyas I, Zheng X, Luo S, Little PJ, Kamato D, Sahebkar A, Wu W, Weng J, et al. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics. 2021;11(9):4502\u201315.","journal-title":"Theranostics"},{"key":"1789_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.","journal-title":"Int J Surg"},{"key":"1789_CR14","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. Cochrane Handbook for Systematic Reviews of Interventions version 6.2; 2021."},{"key":"1789_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"issue":"7109","key":"1789_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"1","key":"1789_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17(1):39.","journal-title":"BMC Med Res Methodol"},{"issue":"22","key":"1789_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"1789_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"3","key":"1789_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2337\/dc14-1237","volume":"38","author":"B Neal","year":"2014","unstructured":"Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2014;38(3):403\u201311.","journal-title":"Diabetes Care"},{"issue":"7","key":"1789_CR21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/dc14-0315","volume":"38","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Leiter LA, de Bruin TWA, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38(7):1218\u201327.","journal-title":"Diabetes Care"},{"issue":"15","key":"1789_CR22","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"24","key":"1789_CR23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1789_CR24","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573\u2013m4573.","journal-title":"BMJ"},{"issue":"6","key":"1789_CR25","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/ehf2.13169","volume":"7","author":"J Butler","year":"2020","unstructured":"Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, Filippatos G, Coats AJS, Anker SD. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020;7(6):3298\u2013309.","journal-title":"ESC Heart Fail"},{"issue":"10254","key":"1789_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329.","journal-title":"Lancet"},{"issue":"10166","key":"1789_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"5","key":"1789_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177646","volume":"12","author":"G Lee","year":"2017","unstructured":"Lee G, Oh SW, Hwang SS, Yoon JW, Kang S, Joh HK, Kwon H, Kim J, Park D. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: a network meta-analysis. PLoS ONE. 2017;12(5): e0177646.","journal-title":"PLoS ONE"},{"issue":"1","key":"1789_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-021-01276-9","volume":"20","author":"C Lin","year":"2021","unstructured":"Lin C, Zhu X, Cai X, Yang W, Lv F, Nie L, Ji L. SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol. 2021;20(1):91.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1789_CR30","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/jcpt.13588","volume":"47","author":"XX Liao","year":"2022","unstructured":"Liao XX, Li WQ, Peng ZK, Yu HB, Tan J. Three new categories of hypoglycaemic agents and various cardiovascular diseases: a meta-analysis. J Clin Pharm Ther. 2022;47(5):636\u201342.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"1789_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","volume":"52","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, Edwards R, Levin A, Mahaffey KW, Perkovic V, et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke. 2021;52(5):1545\u201356.","journal-title":"Stroke"},{"issue":"1","key":"1789_CR32","doi-asserted-by":"publisher","first-page":"15364","DOI":"10.1038\/s41598-021-94945-4","volume":"11","author":"WH Tsai","year":"2021","unstructured":"Tsai WH, Chuang SM, Liu SC, Lee CC, Chien MN, Leung CH, Liu SJ, Shih HM. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep. 2021;11(1):15364.","journal-title":"Sci Rep"},{"issue":"12","key":"1789_CR33","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582\u201392.","journal-title":"Diabetologia"},{"issue":"9896","key":"1789_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941\u201350.","journal-title":"Lancet"},{"issue":"10","key":"1789_CR35","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1789_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/dom.12428","volume":"17","author":"B Bode","year":"2015","unstructured":"Bode B, Stenl\u00f6f K, Harris S, Sullivan D, Fung A, Usiskin K, Meininger G. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294\u2013303.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1789_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2337\/dc15-1736","volume":"39","author":"J Rosenstock","year":"2016","unstructured":"Rosenstock J, Chuck L, Gonz\u00e1lez-Ortiz M, Merton K, Craig J, Capuano G, Qiu R. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-na\u00efve type 2 diabetes. Diabetes Care. 2016;39(3):353\u201362.","journal-title":"Diabetes Care"},{"issue":"11","key":"1789_CR38","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1789_CR39","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.2337\/dc11-0606","volume":"34","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Del Prato S, Meier JJ, Dur\u00e1n-Garc\u00eda S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015\u201322.","journal-title":"Diabetes Care"},{"issue":"10","key":"1789_CR40","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","volume":"13","author":"K Strojek","year":"2011","unstructured":"Strojek K, Yoon K, Hruba V, Elze M, Langkilde A, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928\u201338.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1789_CR41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","volume":"66","author":"R Henry","year":"2012","unstructured":"Henry R, Murray A, Marmolejo M, Hennicken D, Ptaszynska A, List J. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446\u201356.","journal-title":"Int J Clin Pract"},{"key":"1789_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43\u201343.","journal-title":"BMC Med"},{"issue":"7","key":"1789_CR43","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/jgs.12881","volume":"62","author":"LA Leiter","year":"2014","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62(7):1252\u201362.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"1789_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/dom.12187","volume":"16","author":"J Wilding","year":"2014","unstructured":"Wilding J, Woo V, Rohwedder K, Sugg J, Parikh S, Group DS. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obesity Metab. 2014;16(2):124\u201336.","journal-title":"Diabetes Obesity Metab"},{"issue":"4","key":"1789_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/dme.12624","volume":"32","author":"CJ Bailey","year":"2015","unstructured":"Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med. 2015;32(4):531\u201341.","journal-title":"Diabet Med"},{"issue":"3","key":"1789_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2337\/dc14-0666","volume":"38","author":"S Matthaei","year":"2015","unstructured":"Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S. Group ftS: dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized double-blind clinical trial. Diabetes Care. 2015;38(3):365\u201372.","journal-title":"Diabetes Care"},{"issue":"11","key":"1789_CR47","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1111\/dom.13437","volume":"20","author":"D M\u00fcller-Wieland","year":"2018","unstructured":"M\u00fcller-Wieland D, Kellerer M, Cypryk K, Skripova D, Rohwedder K, Johnsson E, Garcia-Sanchez R, Kurlyandskaya R, Sj\u00f6str\u00f6m CD, Jacob S, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(11):2598\u2013607.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1789_CR48","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1111\/dom.13473","volume":"20","author":"R Scott","year":"2018","unstructured":"Scott R, Morgan J, Zimmer Z, Lam RLH, O\u2019Neill EA, Kaufman KD, Engel SS, Raji A. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: the CompoSIT-R study. Diabetes Obes Metab. 2018;20(12):2876\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1789_CR49","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","volume":"20","author":"P Fioretto","year":"2018","unstructured":"Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sj\u00f6str\u00f6m CD, Sartipy P, Investigators DS. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes Obes Metab. 2018;20(11):2532\u201340.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1789_CR50","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/1753-0407.12634","volume":"10","author":"W Yang","year":"2018","unstructured":"Yang W, Ma J, Li Y, Li Y, Zhou Z, Kim JH, Zhao J, Ptaszynska A. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: a randomized controlled trial. J Diabetes. 2018;10(7):589\u201399.","journal-title":"J Diabetes"},{"issue":"11","key":"1789_CR51","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.2337\/dc12-2673","volume":"36","author":"H-U H\u00e4ring","year":"2013","unstructured":"H\u00e4ring H-U, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC. Investigators E-RMT: Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396\u2013404.","journal-title":"Diabetes Care"},{"issue":"12","key":"1789_CR52","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36(12):4015\u201321.","journal-title":"Diabetes Care"},{"issue":"5","key":"1789_CR53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC. investigators E-RRt: efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369\u201384.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1789_CR54","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC. Investigators obotE-RMT: improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815\u201323.","journal-title":"Diabetes Care"},{"key":"1789_CR55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle HJ, Broedl UC. investigators E-REGEM: safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154\u2013154.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1789_CR56","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. investigators E-RBt: impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936\u201348.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1789_CR57","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/dom.12464","volume":"17","author":"E Araki","year":"2015","unstructured":"Araki E, Tanizawa Y, Tanaka Y, Taniguchi A, Koiwai K, Kim G, Salsali A, Woerle HJ, Broedl UC. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17(7):665\u201374.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1789_CR58","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2337\/dc16-0522","volume":"39","author":"S Hadjadj","year":"2016","unstructured":"Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care. 2016;39(10):1718\u201328.","journal-title":"Diabetes Care"},{"issue":"12","key":"1789_CR59","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1111\/dom.13457","volume":"20","author":"M Ridderstr\u00e5le","year":"2018","unstructured":"Ridderstr\u00e5le M, Rosenstock J, Andersen KR, Woerle HJ, Salsali A. investigators ERHHSt: empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. Diabetes Obes Metab. 2018;20(12):2768\u201377.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1789_CR60","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg S\u00d8, Lingvay I, S\u00f8ndergaard AL, Treppendahl MB, Montanya E, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care. 2019;42(12):2272\u201381.","journal-title":"Diabetes Care"},{"issue":"5","key":"1789_CR61","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.13194","volume":"20","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1789_CR62","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/dom.13103","volume":"20","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Frias J, P\u00e1ll D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20(3):520\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1789_CR63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","volume":"9","author":"G Grunberger","year":"2018","unstructured":"Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, Jiang ZW, Golm G, Engel SS, Lauring B. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1):49\u201366.","journal-title":"Diabetes Ther"},{"issue":"3","key":"1789_CR64","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/dom.13116","volume":"20","author":"S Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, Huyck S, Golm G, Terra SG, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530\u201340.","journal-title":"Diabetes Obes Metab"},{"key":"1789_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1583450","author":"P Hollander","year":"2019","unstructured":"Hollander P, Hill J, Johnson J, Jiang ZW, Golm G, Huyck S, Terra SG, Mancuso JP, Engel SS, Lauring B. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2019. https:\/\/doi.org\/10.1080\/03007995.2019.1583450.","journal-title":"Curr Med Res Opin"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01789-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01789-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01789-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T15:07:40Z","timestamp":1678720060000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01789-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1789"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01789-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"21 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}